66 research outputs found
Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma
Get PDFThe antibody-drug conjugate (ADC) cAC10-vcMMAE consists of the tubulin inhibitor monomethyl auristatin E (MMAE) conjugated to the chimeric anti-CD30 monoclonal antibody cAC10. This ADC potently interferes with the growth of CD30-positive haematological tumours, including Hodgkin lymphoma (HL) and anaplastic large-cell lymphoma. This study found improved antitumour activity in a preclinical model of HL when SGN-35 was combined with chemotherapeutic regimens such as ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) or gemcitabine. Improved efficacy was also observed in high tumour burden models, indicating that combining ADCs with chemotherapeutic agents may be advantageous for the treatment of patients with relapsed or refractory HL
The role of drug concentration, duration of exposure and endogeneous metabolites in determining methotrexate cytotoxicity
No full textEvidence for early recruitment of granulocyte precursors during high dose methotrexate infusion in mice
No full textThe reversal of methotrexate cytotoxicity to mouse bone marrow cells by leucovorin and nucleosides
No full textThe relative contribution of drug concentration and duration of exposure to mouse bone marrow toxicity during continuous methotrexate infusion
No full textInhibition of Tenon's Fibroblast Proliferation and Enhancement of Filtration Surgery in Rabbits with Cytosine Arabinoside
No full textTrabeculectomy with Multiple Applications of Mitomycin-C in Monkeys with Experimental Glaucoma
No full text- …
